TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+3.73%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$3.11B
AUM Growth
+$28.3M
(+0.92%)
Cap. Flow
+$26.2M
Cap. Flow
% of AUM
0.84%
Top 10 Holdings %
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34
Top Buys
| 1 |
Rallybio
RLYB
|
$37.6M |
| 2 |
Guardant Health
GH
|
$28.7M |
| 3 |
Idexx Laboratories
IDXX
|
$27.9M |
| 4 |
Amgen
AMGN
|
$23.7M |
| 5 |
AstraZeneca
AZN
|
$21.9M |
Top Sells
| 1 |
Elevance Health
ELV
|
$34.7M |
| 2 |
ResMed
RMD
|
$32.6M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$22.2M |
| 4 |
DexCom
DXCM
|
$21.8M |
| 5 |
Ascendis Pharma
ASND
|
$13.7M |
Sector Composition
| 1 | Healthcare | 96.51% |
| 2 | Real Estate | 2.72% |
| 3 | Industrials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Health Care Select Sector SPDR Fund
XLV
$33.8B
| $16.9M | 0.54% |
132,830
-56,100
| -30% | -$7.14M |
|
52
Welltower
WELL
$112B
| $16.7M | 0.54% |
203,083
| – | – |
|
53
Caribou Biosciences
CRBU
$176M
| $15.6M | 0.5% |
+699,377
| New | +$15.6M |
|
54
Jazz Pharmaceuticals
JAZZ
$7.99B
| $14.9M | 0.48% |
114,059
+46,603
| +69% | +$6.07M |
|
|
MRTX
55
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $14.8M | 0.48% |
83,784
| – | – |
|
56
Ventas
VTR
$30.7B
| $13.7M | 0.44% |
248,131
+40,023
| +19% | +$2.21M |
|
57
Arrowhead Research
ARWR
$3.84B
| $12.7M | 0.41% |
204,214
+71,328
| +54% | +$4.45M |
|
58
Ultragenyx Pharmaceutical
RARE
$3.04B
| $12.7M | 0.41% |
140,726
+6,136
| +5% | +$553K |
|
|
BHVN
59
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $12.6M | 0.41% |
+90,799
| New | +$12.6M |
|
60
CVS Health
CVS
$93B
| $12.5M | 0.4% |
147,453
| – | – |
|
|
KRTX
61
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $12.3M | 0.4% |
100,458
| – | – |
|
|
ITCI
62
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.1M | 0.39% |
324,401
+121,645
| +60% | +$4.54M |
|
63
Neurocrine Biosciences
NBIX
$13.5B
| $12M | 0.38% |
124,609
-88,282
| -41% | -$8.47M |
|
|
IMAB
64
I-MAB
IMAB
$380M
| $11.8M | 0.38% |
162,580
| – | – |
|
65
argenx
ARGX
$44.2B
| $11.6M | 0.37% |
38,456
-35,954
| -48% | -$10.9M |
|
66
Alkermes
ALKS
$4.95B
| $11.5M | 0.37% |
+373,824
| New | +$11.5M |
|
67
Adaptive Biotechnologies
ADPT
$1.96B
| $11.5M | 0.37% |
337,722
| – | – |
|
68
Denali Therapeutics
DNLI
$2.24B
| $11.2M | 0.36% |
222,420
+72,334
| +48% | +$3.65M |
|
69
Novartis
NVS
$248B
| $11.1M | 0.36% |
136,225
| – | – |
|
70
Ionis Pharmaceuticals
IONS
$9.64B
| $10.8M | 0.35% |
322,521
| – | – |
|
|
71
Ascendis Pharma
ASND
$12.1B
| $10.8M | 0.35% |
67,794
-85,842
| -56% | -$13.7M |
|
72
Becton Dickinson
BDX
$54.3B
| $10.6M | 0.34% |
44,390
| – | – |
|
73
Waters Corp
WAT
$17.3B
| $10.2M | 0.33% |
28,461
-19,845
| -41% | -$7.09M |
|
74
BioMarin Pharmaceuticals
BMRN
$11.3B
| $9.89M | 0.32% |
128,004
| – | – |
|
75
Owens & Minor
OMI
$423M
| $9.23M | 0.3% |
294,967
+28,944
| +11% | +$906K |
|